Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories

NCT04469686 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-07-30

No results posted yet for this study

Summary

A randomized, multi-center, double-blind, three arm placebo-controlled study in male and non-pregnant, non-lactating female subjects aged 18 years to examine the safety and efficacy of two dosing regimens of hydrocortisone acetate 90 mg suppository administered with the Sephure applicator for the treatment of ulcerative colitis of the rectum.

Conditions

  • Ulcerative Proctitis

Interventions

COMBINATION_PRODUCT

Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator

Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator

COMBINATION_PRODUCT

Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator

Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator

COMBINATION_PRODUCT

Twice daily placebo suppository administered with Sephure applicator

Twice daily placebo suppository administered with Sephure applicator

Sponsors & Collaborators

  • Cristcot HCA LLC

    collaborator INDUSTRY
  • Cristcot LLC

    lead INDUSTRY

Principal Investigators

  • Jennifer Davagian · Cristcot LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-10
Primary Completion
2024-07-16
Completion
2024-09-19
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States
  • Bulgaria
  • China
  • Denmark
  • France
  • Georgia
  • Germany
  • India
  • Italy
  • Jordan
  • Lebanon
  • Libya
  • Moldova
  • Philippines
  • Poland
  • Romania
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Turkey (Türkiye)
  • Ukraine
  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04469686 on ClinicalTrials.gov